新型非甾体抗炎药吡罗昔康的药理学、临床疗效及不良反应

Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent.

作者信息

Dahl S L, Ward J R

出版信息

Pharmacotherapy. 1982 Mar-Apr;2(2):80-90. doi: 10.1002/j.1875-9114.1982.tb03178.x.

DOI:10.1002/j.1875-9114.1982.tb03178.x

Abstract

Piroxicam, a new non-steroidal anti-inflammatory drug, possesses analgesic, antipyretic, and anti-inflammatory properties and inhibits platelet aggregation in animal models. Its elimination half-life is 38 hours, and hepatic metabolism to inactive metabolites is the primary route of elimination. Less than 10% of a dose appears unchanged in the urine. Clinical studies demonstrate that piroxicam's analgesic and anti-inflammatory properties are useful in the management of rheumatoid arthritis and osteoarthritis. Limited clinical studies suggest that piroxicam may be useful in the management of acute gouty arthritis, ankylosing spondylitis, acute musculoskeletal disorders, and as an analgesic. The gastrointestinal system is the major site of adverse effects. Piroxicam is currently marketed in 20 mg capsules and once daily dosing has proven effective for many patients.

摘要

吡罗昔康是一种新型非甾体抗炎药，具有镇痛、解热和抗炎特性，并在动物模型中抑制血小板聚集。其消除半衰期为38小时，经肝脏代谢为无活性代谢产物是主要消除途径。给药剂量中不到10%以原形出现在尿液中。临床研究表明，吡罗昔康的镇痛和抗炎特性对类风湿性关节炎和骨关节炎的治疗有用。有限的临床研究表明，吡罗昔康可能对急性痛风性关节炎、强直性脊柱炎、急性肌肉骨骼疾病的治疗有用，还可作为镇痛药。胃肠道系统是不良反应的主要发生部位。吡罗昔康目前以20毫克胶囊形式上市，每日一次给药已被证明对许多患者有效。